Fabien Guidez

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7841579/publications.pdf

Version: 2024-02-01

29	2,131	516710 16	552781 26
papers	citations	h-index	g-index

30	30	30	2680
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Human CREBBP acetyltransferase is impaired by etoposide quinone, an oxidative and leukemogenic metabolite of the anticancer drug etoposide through modification of redox-sensitive zinc-finger cysteine residues. Free Radical Biology and Medicine, 2021, 162, 27-37.	2.9	9
2	PLZF Acetylation Levels Regulate NKT Cell Differentiation. Journal of Immunology, 2021, 207, 809-823.	0.8	5
3	The Benzene Hematotoxic and Reactive Metabolite 1,4-Benzoquinone Impairs the Activity of the Histone Methyltransferase SET Domain Containing 2 (SETD2) and Causes Aberrant Histone H3 Lysine 36 Trimethylation (H3K36me3). Molecular Pharmacology, 2021, 100, 283-294.	2.3	5
4	BCL-2 Inhibitor ABT-737 Effectively Targets Leukemia-Initiating Cells with Differential Regulation of Relevant Genes Leading to Extended Survival in a NRAS/BCL-2 Mouse Model of High Risk-Myelodysplastic Syndrome. International Journal of Molecular Sciences, 2021, 22, 10658.	4.1	4
5	T-Cell Protein Tyrosine Phosphatase Is Irreversibly Inhibited by Etoposide-Quinone, a Reactive Metabolite of the Chemotherapy Drug Etoposide. Molecular Pharmacology, 2019, 96, 297-306.	2.3	9
6	GEP analysis validates high risk MDS and acute myeloid leukemia post MDS mice models and highlights novel dysregulated pathways. Journal of Hematology and Oncology, 2016, 9, 5.	17.0	10
7	A RP-UFLC Assay for Protein Tyrosine Phosphatases: Focus on Protein Tyrosine Phosphatase Non-Receptor Type 2 (PTPN2). Scientific Reports, 2015, 5, 10750.	3.3	7
8	Post transcriptional control of the epigenetic stem cell regulator PLZF by sirtuin and HDAC deacetylases. Epigenetics and Chromatin, 2015, 8, 38.	3.9	11
9	HDAC4 as a potential therapeutic target in neurodegenerative diseases: a summary of recent achievements. Frontiers in Cellular Neuroscience, 2015, 9, 42.	3.7	90
10	An acetyltransferase assay for CREB-binding protein based on reverse phaseâ€“ultra-fast liquid chromatography of fluorescent histone H3 peptides. Analytical Biochemistry, 2015, 486, 35-37.	2.4	17
11	Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network. Nature Genetics, 2015, 47, 1334-1340.	21.4	152
12	The epigenetic regulator PLZF represses L1 retrotransposition in germ and progenitor cells. EMBO Journal, 2013, 32, 1941-1952.	7.8	41
13	Retinoic Acid Receptors. , 2010, , 237-258.		0
14	Acute Promyelocytic Leukemia: A Paradigm for Differentiation Therapy. Cancer Treatment and Research, 2009, 145, 219-235.	0.5	61
15	Defining the Landscape of Resistance Mutations in the Context of Modern Treatment Protocols for Acute Promyelocytic Leukemia (APL).. Blood, 2008, 112, 1492-1492.	1.4	0
16	RARÎ±-PLZF overcomes PLZF-mediated repression of CRABPI , contributing to retinoid resistance in t(11;17) acute promyelocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18694-18699.	7.1	62
17	Histone Acetyltransferase Activity of p300 Is Required for Transcriptional Repression by the Promyelocytic Leukemia Zinc Finger Protein. Molecular and Cellular Biology, 2005, 25, 5552-5566.	2.3	99
18	Benzodithiophenes Potentiate Differentiation of Acute Promyelocytic Leukemia Cells by Lowering the Threshold for Ligand-Mediated Corepressor/Coactivator Exchange with Retinoic Acid Receptor Î± and Enhancing Changes in all-trans-Retinoic Acidâ€“Regulated Gene Expression. Cancer Research, 2005, 65, 7856-7865.	0.9	11

#	Article	IF	Citations
19	Rexinoid-Triggered Differentiation and Tumor-Selective Apoptosis of Acute Myeloid Leukemia by Protein Kinase Aâ€"Mediated Desubordination of Retinoid X Receptor. Cancer Research, 2005, 65, 8754-8765.	0.9	111
20	Synthesis and Evaluation of a Potent and Selective Cell-Permeable p300 Histone Acetyltransferase Inhibitor. Journal of the American Chemical Society, 2005, 127, 17182-17183.	13.7	63
21	1Î±,25-Dihydroxyvitamin D3Transrepresses Retinoic Acid Transcriptional Activity via Vitamin D Receptor in Myeloid Cells. Molecular Endocrinology, 2004, 18, 2685-2699.	3.7	37
22	Histone Acetyltransferase Activity of p300 Is Required for Transcriptional Repression by the Promyelocytic Leukemia Zinc Finger Protein.. Blood, 2004, 104, 359-359.	1.4	0
23	Regulation of Hoxb2 by APL-associated PLZF protein. Oncogene, 2003, 22, 3685-3697.	5.9	39
24	The Histone Deacetylase 9 Gene Encodes Multiple Protein Isoforms. Journal of Biological Chemistry, 2003, 278, 16059-16072.	3.4	128
25	Translocations of the RARÎ± gene in acute promyelocytic leukemia. Oncogene, 2001, 20, 7186-7203.	5.9	206
26	Colocalization and heteromerization between the two human oncogene POZ/zinc finger proteins, LAZ3 (BCL6) and PLZF. Oncogene, 2000, 19, 6240-6250.	5.9	66
27	Distinct interactions of PML-RARÎ± and PLZF-RARÎ± with co-repressors determine differential responses to RA in APL. Nature Genetics, 1998, 18, 126-135.	21.4	566
28	Differential Utilization of Ras Signaling Pathways by Macrophage Colony-Stimulating Factor (CSF) and Granulocyte-Macrophage CSF Receptors during Macrophage Differentiation. Molecular and Cellular Biology, 1998, 18, 3851-3861.	2.3	31
29	Reduced Retinoic Acid-Sensitivities of Nuclear Receptor Corepressor Binding to PML- and PLZF-RARÎ± Underlie Molecular Pathogenesis and Treatment of Acute Promyelocytic Leukemia. Blood, 1998, 91, 2634-2642.	1.4	291